Top Novartis exec in India says two plants warned by FDA completing remediation

Novartis India Managing Director Ranjit Shahani told India's PTI that the drugmaker expects upgrades at two Sandoz plants that were issued a warning letter by the FDA to soon be back to full production. We have already taken remedial action at these plants and these units would be soon back to normal," he told the news service. Novartis ($NVS) CEO Joseph Jimenez acknowledged during the Q3 earnings call last month that the FDA issued the warning letter for the sites in Kalwe as well as one in Turbhe, a plant that Sandoz intends to close. Story | More

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.